Trial Profile
Nonrandomized, open-label, fixed-sequence, two-period prospective study of desipramine and rabusertib, in patients with advanced or metastatic cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Sep 2015
Price :
$35
*
At a glance
- Drugs Rabusertib (Primary) ; Desipramine
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 23 Sep 2015 New trial record